IOVS Annual Reviews: Biomedical Science Suite
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dijkstra, B. G.
Right arrow Articles by Hoyng, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dijkstra, B. G.
Right arrow Articles by Hoyng, P. F.
(Investigative Ophthalmology and Visual Science. 1999;40:2622-2626.)
© 1999 by The Association for Research in Vision and Ophthalmology, Inc.

Flow after Prostaglandin E1 Is Mediated by Receptor-Coupled Adenylyl Cyclase in Human Anterior Segments

Berlinde G. Dijkstra, Andrea Schneemann and Philip F. Hoyng

From The Netherlands Ophthalmic Research Institute, Amsterdam, The Netherlands.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
PURPOSE. To assess the effect of prostaglandin (PG) F2{alpha} and PGE1 on flow through the trabecular meshwork in organ preserved human anterior segments.

METHODS. Isolated human anterior segments were perfused under standard conditions at a constant pressure of 10 mm Hg, while flow was continuously monitored. After a stabilization period, 6 consecutive concentrations of PGs were administered. cAMP levels were determined in the perfusate at baseline conditions and at 10-6 M PG.

RESULTS. Perfusion with concentrations ranging from 10-10 to 10-5 M PGE1 resulted in a dose-dependent increase in flow (P < 0.0001), reaching a plateau of a 26% increase at 10-7 M. Perfusion with PGF2{alpha} or placebo (Eagle’s minimum essential medium) did not influence baseline flow. cAMP produced by human anterior segments increased from 4.8 ± 0.6 pmol · 30 min-1 per anterior segment at baseline to 19.2 ± 4.8 pmol · 30 min-1 per anterior segment after perfusion with 10-6 M PGE1 (P < 0.005). Perfusion with 10-6 M PGF2{alpha} did not influence baseline cAMP production. Perfusion with 10-5 M GDP–ß–S, an inhibitor of G protein, before and in combination with 10-6 M PGE1 completely inhibited the increase in flow and cAMP production as observed after PGE1 alone. Perfusion with 10-5 M GDP–ß–S alone did not affect baseline cAMP production.

CONCLUSIONS. In organ preserved perfused human anterior segments, flow and cAMP production in the perfusate are not mediated by receptor-coupled adenylyl cyclase activity at baseline conditions. Perfusion with PGE1 is suggested to increase flow through the trabecular meshwork by stimulation of prostanoid EP2 receptor subtype, EP4 receptor subtype, or both, coupled to G(s) protein, inducing activation of the adenylyl cyclase catalytic unit. The results may indicate a physiological role for EP2 receptor subtype, EP4 receptor subtype, or both in the modulation of flow through the trabecular meshwork after stimulation.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
There is ample evidence that prostaglandin (PG) F2{alpha} analogues lower intraocular pressure (IOP) in glaucoma.1 2 3 4 The main mechanism of action by which these analogues are thought to lower IOP is not by increasing trabecular flow but rather by stimulating aqueous humor flow through the uveoscleral channels as was shown in primates, including humans.5 6 7 8

In primates PGF2{alpha}, as well as PGE1 and PGE2, administered intracamerally, did not induce an increase of outflow facility, both in normal eyes and in eyes after disinsertion or retrodisplacement of the ciliary muscle.9 It was then concluded that in general PGs do not lower IOP via a direct effect on the trabecular meshwork.

Cultured human trabecular cells have been demonstrated to generate PGE2 and to a lower extent PGF2{alpha} and 6-keto PGF1{alpha}, the stable end product of prostacyclin (PGI2).10 11 Incubations of rabbit sclera trabecular rings with PGE1 revealed an increase of cAMP.12 In human trabecular meshwork membrane fractions, PGE1 and PGE2, but not PGF2{alpha}, stimulated adenylyl cyclase activity.13 Adenosine 3'–5'–monophosphate is known to increase outflow facility in rabbit and monkey eyes and 8-bromo–cAMP lowers IOP in rabbits.14 15 16

Because in human trabecular meshwork membrane fractions, PGE1 is linked to the adenylyl cyclase system and PGF2{alpha} is not, and because cAMP increases outflow facility in rabbit and monkey eyes, it would be of interest to investigate the effect of these PGs on trabecular flow in the human eye.

The present study reports the effect of a wide-range dose of PGE1 and PGF2{alpha} on the flow through the trabecular meshwork of organ preserved human anterior segments.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Human eyes were obtained from the Cornea Bank at the Netherlands Ophthalmic Research Institute. The eyes were discarded because of corneal pathology. Under sterile conditions the eyes were dissected as reported previously.17 The corneoscleral explants were mounted on a perfusion apparatus and connected to a real-time flow measurement system.18 19 The pressure was computer-link adjusted and maintained at the constant level of 10 mm Hg. Flow through the trabecular meshwork was also monitored by the computer. Every 20 seconds the actual pressure and flow rate were sampled. Under standard conditions (5% CO2 and at 35°C) the eyes were perfused with modified Eagle’s minimum essential medium (EMEM) containing 2% fetal bovine serum (final protein concentration 0.4%), 100 µg · ml-1 penicillin, and 50 µg · ml-1 streptomycin.

After a stabilization period of 2 hours, 6 consecutive concentrations of PGE1 (11,13–dihydroxy–9–oxo–(11{alpha},13E,15S)–prost–13–en–1–oic acid), PGF2{alpha}–TS (both from Sigma Chemical, St Louis, MO) or placebo (EMEM) were administered at 60-minute intervals. The concentrations of the prostaglandins were 10-10, 10-9, 10-8, 10-7, 10-6, and 10-5 M, respectively. In addition, the effects of 10-6 M PGE1 after and in combination with 10-5 M GDP–ß–S (Fluka Chemie AG, Buchs, Switzerland) were assessed. At baseline and after perfusion with 10-6 M PG, perfusate was collected and immediately frozen at -70°C for later cAMP detection. An enzyme Immunoassay Kit (Cayman Chemical, Ann Arbor, MI) was used to determine cAMP concentrations in the samples after acetylation and purification. The amount of cAMP was calculated as picomoles produced per anterior segment for 30 minutes after a drug administration. Baseline flow rate was defined as the mean flow during the last 15 minutes before drug administration. Mean flows for each interval were calculated from the equilibrated period of that interval. Difference in flow was expressed in percent by Flow Exp/Flow baseline x 100% - 100%.

In addition, total lactate dehydrogenase activity (LDH) was measured hourly in 10 µl perfusate of 5 human anterior segments, perfused for 2 hours with plain medium and 1 hour with 10-6 M PGE1.20 LDH activity was expressed in U · 30 min-1 per anterior segment (U = µmol · min-1).

Data were expressed as mean ± SD for age and postmortem times and with standard error of the mean for flow, cAMP, and LDH data. Statistical analyses of data were performed using a repeated-measures ANOVA, a Newman–Keuls test, and the two-sided paired Student’s t-test.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
The mean age and the mean postmortem times of the donors that provided the eyes for organ preserved perfusion are listed in Table 1 . A typical flow rate tracing of one of the treated eyes is shown in Figure 1 .


View this table:
[in this window]
[in a new window]
  		Table 1. Mean Age and Mean Postmortem Time of Donor Eyes

 


View larger version (10K):
[in this window]
[in a new window]
  		Figure 1. Typical flow rate tracing of a human anterior segment after addition of 6 consecutive concentrations of PGE1.

 
Baseline flow in the PGE1 group (n = 7) was 4.1 ± 0.5 µl · min-1 and increased in a dose-dependent fashion after perfusion with all concentrations of PGE1 used (P < 0.0001, repeated-measures ANOVA, followed by Newman–Keuls test). Table 2 shows an overview of the data. The plateau of trabecular flow of 26% reached at 10-7 M PGE1 (EC50: 10-9 M) can be distinguished. In contrast, none of the concentrations of PGF2{alpha} used affected flow through the trabecular meshwork. Baseline flow in the PGF2{alpha} group (n = 7) was 3.6 ± 0.5 µl · min-1 and showed a tendency only to decrease at the highest concentrations of PGF2{alpha} (10-6 and 10-5 M). Baseline flow in the placebo group (n = 7) perfused with EMEM was 4.0 ± 1.0 µl · min-1 and did not change significantly after consecutive administration of placebo at time intervals similar to those with the PGs.


View this table:
[in this window]
[in a new window]
  		Table 2. Mean Flow ± SEM in Organ Preserved Human Anterior Segments at Baseline, after Increasing Doses of PGE1 and PGF2{alpha}, during EMEM (Placebo), and after 10-5 M GDP–ß–S Alone, Followed by 10-5 M GDP–ß–S in Combination with 10-6 M PGE1

 
GDP–ß–S, an inhibitor of G proteins, was perfused for 60 minutes in a concentration of 10-5 M before administration of the combination of 10-6 M PGE1 and 10-5 M GDP–ß–S in 8 human anterior segments.21 Table 2 shows that the baseline flow was 2.8 ± 0.3 µl · min-1 and 3.4±0.4 µl · min-1 after 10-5 M GDP–ß–S. Perfusion with 10-5 M GDP–ß–S and 10-6 M PGE1 together did result in a flow of 3.5 ± 0.5 µl · min-1, which is not significantly different from the flow after GDP–ß–S alone.

The cAMP levels after perfusion with 10-6 M PGE1 and 10-6 M PGF2{alpha} are also listed in Table 2 . In the PGE1 group baseline cAMP was 4.8 ± 0.6 pmol · 30 min-1 per anterior segment and increased after 10-6 M PGE1 to 19.2 ± 4.8 pmol · 30 min-1 per anterior segment (P < 0.005); the average stimulation index was 3.9. In the PGF2{alpha} group baseline cAMP in the perfusate was 4.2 ± 1.4 pmol · 30 min-1 per anterior segment and did not differ after perfusion with 10-6 M PGF2{alpha} (3.7 ± 0.7 pmol · 30 min-1 per anterior segment).

Baseline cAMP before perfusion with 10-5 M GDP–ß–S was 3.4 ± 0.7 pmol · 30 min-1 per anterior segment and was 3.8 ± 1.1 pmol · 30 min-1 per anterior segment during perfusion with GDP–ß–S. Perfusion with 10-5 M GDP–ß–S together with 10-6 M PGE1 resulted in a cAMP production of 3.8 ± 1.0 pmol · 30 min-1 per anterior segment.

There was no significant difference between the cAMP values after perfusion with GDP–ß–S alone and the combination of GDP–ß–S and PGE1.

Additional perfusion of 5 anterior segments with EMEM resulted in a LDH activity of 0.047 ± 0.015 U · 30 min-1 during the first hour and 0.036 ± 0.007 U · 30 min-1 during the second hour. Subsequent perfusion with 10-6 M PGE1 resulted in a LDH activity of 0.026 ± 0.009 U · 30 min-1.


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In this study PGE1, but not PGF2{alpha}, increased flow through the trabecular meshwork. The amount of cAMP produced by human anterior segments increased approximately fourfold from baseline values after perfusion with 10-6 M PGE1.

In a previous study we observed that in bovine trabecular meshwork particulate fractions, adenylyl cyclase was stimulated by PGE1 and PGE2 but not by PGF2{alpha}.13 Furthermore, the stimulation of adenylyl cyclase by PGE1 was dose dependent. It was shown that GDP–ß–S, known to inhibit G proteins irreversibly, downregulated PGE1-stimulated adenylyl cyclase activity. Also, in membrane preparations of human trabecular meshwork, PGE1 and PGE2 stimulated adenylyl cyclase activity. It was then concluded that bovine and human trabecular meshwork contained prostanoid EP receptor sites of the subtype bound to adenylyl cyclase.

An increase in flow after perfusion with PGE1, as observed in this study, may not originate from an increase in cAMP production, since both events may exist independently. Therefore, the relation of the increase in flow with a possible receptor-mediated activity of PGE1 to stimulate adenylyl cyclase via G proteins was tested by perfusion with GDP–ß–S in the presence and absence of PGE1. Because GDP–ß–S hardly has an influence on basal adenylyl cyclase activity, it is suggested that the baseline cAMP level is not originating from receptor-coupled adenylyl cyclase activity.

The combination of GDP–ß–S and PGE1 completely inhibited the increase in flow through the meshwork and the increase of cAMP in perfusate as observed after PGE1 alone.

From this it is concluded that after perfusion of human anterior segments with PGE1 the increase of flow through the trabecular meshwork is mediated by receptor-bound adenylyl cyclase activity. This indicates that EP receptors either of the subtype EP2, subtype EP4, or both not only are present in human trabecular meshwork but also may play a physiological role by promoting trabecular flow after stimulation.13 22 23

cAMP is known to be a poorly permeable intracellular messenger. However, many studies show cAMP levels extracellularly in vitro of intact cells or whole tissue preparations and in vivo, for instance in the aqueous humor.12 13 24 25 26 27 28 29 30 31 32 In those studies, agents upregulating intracellular cAMP show an increase in cAMP in supernatant or in the aqueous humor. Because cAMP is not easily permeable, studies can give no quantitative information on the upregulation of the catalytic unit intracellularly, and the amount is only a faint expression of the events occurring intracellularly. Therefore, data on extracellular cAMP should be considered only qualitatively as an up- or downregulation of intracellular cAMP. It can be argued that 10-6 M PGE1 is toxic and induces lysis of cells lining the cornea and outflow pathways, resulting in a continuous release of intracellular cAMP in the perfusate. This could be the explanation of the increase of cAMP in perfusate after PGE1, but not the absence of the increase after PGF2{alpha}, unless the latter PG is not toxic. To investigate this, we determined LDH activity in perfusate in the presence and absence of PGE1. LDH is an intracellular enzyme in the cytosol. The activity found in extracellular fluid is a measure for cell lysis. The observed LDH activity in perfusate should be considered relatively. Our data clearly show that there is no increase of LDH activity after perfusion with 10-6 M PGE1. From this it is concluded that the increased levels of cAMP after PGE1 cannot be the result of cell lysis. Moreover, if cAMP in perfusate was caused by cell lysis, one would expect also an increase of cAMP in perfusate after perfusion with GDP–ß–S and PGE1 together, which was not the case.

Kaufman9 reported hardly any increase in outflow facility in cynomolgus monkeys after intracameral infusion with PGE1, PGE2, and PGF2{alpha} in final concentrations ranging from 3 x 10-7 to 3 x 10-4 M in vivo. However, a 30% to 50% increase of total facility was observed after topical PGE2 in albino rabbits and in rhesus monkeys in vivo.33 34

In our opinion the most fundamental differences between the study of Kaufman and the present study are monkey versus human eyes and perfusion of whole eyes in vivo (iris–ciliary body present) versus anterior segment perfusion. It was stated earlier that human and subhuman eyes differ fundamentally in the composition, cell biology, and physiology of outflow pathways.35 In particular, human eyes do not show evidence of a time-dependent increase of outflow facility (washout).36 In the study of Kaufman,9 the perfusion data were individually decreased by 15% to correct for washout. It is questionable whether the correction for washout in that study obscured an effect of PGE1 on outflow facility. Furthermore, in vivo PGs are rapidly removed from the aqueous by an active transport into the ciliary processes.37 38 39 It is suggested that the uptake of PGs by the ciliary processes in cynomolgus monkeys in vivo may have leveled off the possible effect on outflow facility in that study, whereas in anterior segment perfusion the concentration of PGs in contact with the trabecular outflow tissues is approximately constant. Finally, the differences in results between the study of Kaufman9 and the present study may be the result of species differences pertaining to the presence of functional EP-receptor sites in the trabecular meshwork.

The present study indicates that PGE1 increases flow through the trabecular meshwork in organ preserved human anterior segments by stimulation of EP2, EP4, and/or, receptor sites coupled to G(s)-protein–stimulated adenylyl cyclase activity. It is suggested to design a prostaglandin prodrug stimulating prostanoid FP receptor subtype (FP) as well as EP2 or EP4 receptor subtypes or both. When a potential influence of this prodrug on conjunctival vessels and blood-aqueous barriers can be circumvented, a PG analogue will be available for glaucoma treatment with a dual mechanism on outflow pathways, i.e., on trabecular as well as on uveoscleral flow.


   Acknowledgements
 
The authors thank Elisabeth Pels and coworkers of the Cornea Bank for providing the eyes and the culture medium.


   Footnotes
 
Submitted for publication May 7, 1998; revised April 23, 1999; accepted May 20, 1999.

Commercial relationships policy: N.

Corresponding author: Philip F. Hoyng, The Netherlands Ophthalmic Research Institute, P. O. Box 12141, 1100 AC Amsterdam, The Netherlands. E-mail: ph.hoyng{at}ioi.know.nl


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Alm, A, Stjernschantz, J, . for the Scandinavian Latanoprost Study Group (1995) Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol >Ophthalmology 102,1743-1752[Medline][Order article via Infotrieve]
  2. Camras, CB (1996) , for the United States Latanoprost Study Group Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. Ophthalmology. 103,138-147[Medline][Order article via Infotrieve]
  3. Watson, P, Stjernschantz, J, . for the Latanoprost Study Group (1996) A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension Ophthalmology 103,126-137[Medline][Order article via Infotrieve]
  4. Camras CB, Alm A, Watson P. Glaucoma treatment for 1 year with latanoprost, a prostaglandin analog, in the USA, Scandinavia, and UK. Annual meeting of the American Academy of Ophthalmology, Atlanta; 1995.
  5. Crawford, K, Kaufman, PL (1987) Pilocarpine antagonizes prostaglandin F2{alpha}-induced ocular hypotension in monkeys: evidence for enhancement of uveoscleral outflow by prostaglandin F2{alpha} Arch Ophthalmol 105,1112-1116[Abstract/Free Full Text]
  6. Nilsson, SFE, Samuelsson, M, Bill, A, Stjernschantz, J. (1989) Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2{alpha}-1-isopropylester in the cynomolgus monkey Exp Eye Res 48,707-716[Medline][Order article via Infotrieve]
  7. True Gabelt, BA, Kaufman, PL. (1989) Prostaglandin F2{alpha} increases uveoscleral outflow in the cynomolgus monkey Exp Eye Res 49,389-402[Medline][Order article via Infotrieve]
  8. Toris, CB, Camras, CB, Yablonski, ME (1993) Effects of PhXA41, a new prostaglandin F2{alpha} analog, on aqueous humor dynamics in human eyes Ophthalmology 100,1297-1304[Medline][Order article via Infotrieve]
  9. Kaufman, PL (1986) Effects of intracamerally infused prostaglandins on outflow facility in cynomolgus monkey eyes with intact or retrodisplaced ciliary muscle Exp Eye Res 43,819-827[Medline][Order article via Infotrieve]
  10. Weinreb, RN, Mitchell, MD, Polansky, JR (1983) Prostaglandin production by human trabecular cells: in vitro inhibition by dexamethasone Invest Ophthalmol Vis Sci 24,1541-1545[Abstract/Free Full Text]
  11. Weinreb, RN, Polansky, JR, Alvarado, JA, Mitchell, MD (1988) Arachidonic acid metabolism in human trabecular meshwork cells Invest Ophthalmol Vis Sci 29,1708-1712[Abstract/Free Full Text]
  12. Neufeld, AH, Sears, ML (1974) Cyclic-AMP in ocular tissues of the rabbit, monkey, and human Invest Ophthalmol 13,475-477[Abstract/Free Full Text]
  13. Busch, MJWM, Kobayashi, K, Hoyng, PFJ, Mittag, TW (1993) Adenylyl cyclase in human and bovine trabecular meshwork Invest Ophthalmol Vis Sci 34,3028-3034[Abstract/Free Full Text]
  14. Neufeld, AH, Dueker, DK, Vegge, T, Sears, ML (1975) Adenosine 3',5'-monophosphate increases the outflow of aqueous humor from the rabbit eye Invest Ophthalmol 14,40-42[Abstract/Free Full Text]
  15. Neufeld, AH, Sears, ML (1975) Adenosine 3',5'-monophosphate analogue increase outflow facility of primate eye Invest Ophthalmol 14,688-692[Abstract/Free Full Text]
  16. Busch, MJWM, van Oosterhout, EJGM, Hoyng, PFJ (1992) Effects of cyclic nucleotide analogs on intraocular pressure and trauma-induced inflammation in the rabbit eye Curr Eye Res 11,5-13[Medline][Order article via Infotrieve]
  17. Dijkstra, BG, Ruijter, JM, Hoyng, PF (1996) Outflow characteristics of isolated anterior segments of human eyes Invest Ophthalmol Vis Sci 37,2015-2021[Abstract/Free Full Text]
  18. Erickson, Lamy K, Rohen, JW, Grant, WM (1991) Outflow facility studies in the perfused human ocular anterior segment Exp Eye Res 52,723-731[Medline][Order article via Infotrieve]
  19. Ethier, CR, Ajersch, P, Pirog, R. (1993) An improved ocular perfusion system Curr Eye Res 12,765-770[Medline][Order article via Infotrieve]
  20. Wroblenski, F, La Due, JS (1955) Lactic dehydrogenase activity in blood Proc Soc Exp Biol Med 90,210-214
  21. Eckstein, F, Cassel, D, Levkovitz, H, Lowe, M, Selinger, Z. (1979) Guanosine 5'-0-(2-thiodiphosphate): an inhibitor of adenylate cyclase stimulation by guanine nucleotides and fluoride ions J Biol Chem 254,9829-9834[Free Full Text]
  22. Coleman, RA, Smith, WL, Narumiya, S. (1994) Classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes Pharmacol Rev 46,205-229[Medline][Order article via Infotrieve]
  23. Woodward, DF, Regan, JW, Lake, S, Ocklind, A. (1997) The molecular biology and ocular distribution of prostanoid receptors Surv Ophthalmol 41(suppl 2),15-21
  24. Mittag, TW, Tormay, A. (1985) Drug responses of adenylyl cyclase in iris-ciliary body determined by adenine labeling Invest Ophthalmol Vis Sci 26,396-399[Abstract/Free Full Text]
  25. Cepelic, J, Cernohorsky, M. (1981) The effects of adrenergic agonists and antagonists on the adenylyl cyclase in albino rabbit ciliary process Exp Eye Res 32,291-299[Medline][Order article via Infotrieve]
  26. Koh, SM, Yue, BYT (1988) Effects of agonists on the intracellular cyclic AMP concentration in monkey trabecular meshwork cells Curr Eye Res 7,75-80[Medline][Order article via Infotrieve]
  27. Tripathi, BJ, Tripathi, R. (1984) Effect of epinephrine in vitro on the morphology, phagocytosis, and miotic activity of human trabecular endothelium Exp Eye Res 39,731-744[Medline][Order article via Infotrieve]
  28. Polansky, JR, Zlock, D, Brasier, A, Bloom, E. (1985) Adrenergic and cholinergic receptors in isolated non-pigmented ciliary epithelial cells Curr Eye Res 4,517-522[Medline][Order article via Infotrieve]
  29. Boas, RS, Messenger, MJ, Mittag, TW, Podos, SM (1981) The effects of topically applied epinephrine and timolol on intraocular pressure and aqueous humour cyclic-AMP in the rabbit Exp Eye Res 32,681-690[Medline][Order article via Infotrieve]
  30. Rowland, JM, Potter, DE (1979) Effect of adrenergic drugs on aqueous c-AMP and c-GMP and intraocular pressure Albrecht v Graefes Arch Clin Ophthalmol 212,65-75
  31. Groeneboer, MC, Hoyng, PFJ, Kuizenga, A. (1989) Prostaglandin F2{alpha} isopropyl ester versus Iloprost phenacyl ester in rabbit and beagle eyes Curr Eye Res 8,131-138[Medline][Order article via Infotrieve]
  32. Hoyng, PFJ, Groeneboer, C, Busch, MJWM (1991) Isobutylmethylxanthine enhances adrenergic-induced ocular hypotension in rabbits and beagles Exp Eye Res 52,511-517[Medline][Order article via Infotrieve]
  33. Camras, CB, Bito, LZ, Eakins, KE (1977) Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits Invest Ophthalmol Vis Sci 16,1125-1134[Free Full Text]
  34. Casey, WJ (1974) Prostaglandin E2 and aqueous humor dynamics in the rhesus monkey eye Prostaglandins 8,327-337[Medline][Order article via Infotrieve]
  35. Erickson, Lamy K, Rohen, JW, Grant, WM (1988) Outflow facility studies in the perfused bovine aqueous outflow pathways Curr Eye Res 8,799-807
  36. Erickson, Lamy K, Schroeder, AM, Bassett, C, Epstein, DL (1990) Absence of time dependent facility increase (‘washout’) in the perfused enucleated human eye Invest Ophthalmol Vis Sci 31,2384-2388[Abstract/Free Full Text]
  37. Bito, LZ, Salvador, EV (1972) Intraocular fluid dynamics, III: the site and mechanism of prostaglandin transfer across the blood intraocular fluid barriers Exp Eye Res 14,233-241[Medline][Order article via Infotrieve]
  38. Bito, LZ (1973) Absorptive transport of prostaglandins from intraocular fluids to blood: a review of recent findings Exp Eye Res 16,299-306[Medline][Order article via Infotrieve]
  39. Bito, LZ, Wallenstein, MC (1977) Transport of prostaglandins across the blood-brain and blood-aqueous barriers and the physiological significance of these absorptive transport processes Bito, LZ Davson, H Fenstermacher, J eds. The Ocular and Cerebrospinal Fluids ,229-243 Academic Press London.



This article has been cited by other articles:


Home page
 IOVSHome page
D.-J. Oh, J. L. Martin, A. J. Williams, P. Russell, D. E. Birk, and D. J. Rhee
Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells.
Invest. Ophthalmol. Vis. Sci., September 1, 2006; 47(9): 3887 - 3895.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
J. H Kang, L. R Pasquale, W. C Willett, B. A Rosner, K. M Egan, N. Faberowski, and S. E Hankinson
Dietary fat consumption and primary open-angle glaucoma
Am. J. Clinical Nutrition, May 1, 2004; 79(5): 755 - 764.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
B'A. T. Gabelt, J. L. Seeman, S. M. Podos, T. W. Mittag, and P. L. Kaufman
Aqueous Humor Dynamics in Monkeys after Topical 8-Iso PGE2
Invest. Ophthalmol. Vis. Sci., March 1, 2004; 45(3): 892 - 899.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
N. A. Sharif, C. R. Kelly, and J. Y. Crider
Human Trabecular Meshwork Cell Responses Induced by Bimatoprost, Travoprost, Unoprostone, and other FP Prostaglandin Receptor Agonist Analogues
Invest. Ophthalmol. Vis. Sci., February 1, 2003; 44(2): 715 - 721.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
W. Kamphuis, A. Schneemann, L. M. van Beek, A. B. Smit, P. F. J. Hoyng, and E. Koya
Prostanoid Receptor Gene Expression Profile in Human Trabecular Meshwork: A Quantitative Real-Time PCR Approach
Invest. Ophthalmol. Vis. Sci., December 1, 2001; 42(13): 3209 - 3215.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dijkstra, B. G.
Right arrow Articles by Hoyng, P. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dijkstra, B. G.
Right arrow Articles by Hoyng, P. F.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS